Navigation Links
Prognostic model developed for MDS related to prior cancer therapy
Date:12/13/2011

ssociated with overall survival when considered as isolated, single variables.

Next, the researchers conducted a multi-variable analysis that narrowed factors reducing overall survival to seven:

  • Age 65 or older.
  • ECOG performance status scores of 2-4. (Eastern Cooperative Oncology Group criteria range from 0, which means fully active, to 4, signifying complete disability).
  • Cytogenetics. Having at least seven chromosomal alterations and/or complex cytogenetics.
  • Two MDS subgroups as determined by World Health Organization Criteria. RARS and RAEB-1/2.
  • Serum hemoglobin levels of less than 11g/dL.
  • Platelet levels of less than 50.
  • Dependency on blood transfusions.

Prognostic model sorts patients into three risk groups

Garcia-Manero and colleagues created a novel prognostic model that incorporated these multivariate factors and divided patients into three categories:

  • Good prognosis - 57 patients fell into this group by having 0-2 of the multivariate risk characteristics. Their median survival was 34 months.
  • Intermediate prognosis - 154 patients in this category had 3-4 risk factors and a median survival of 12 months.
  • Poor prognosis - 61 patients had 5-7 risk factors and a median survival of only five months.

The model also predicted one-year leukemia-free survival of 96 percent in the good category, 84 percent for intermediate, and 72 percent for the poor.

Model validated in a test group of patients

The researchers validated the model by applying it to an additional 189 treatment-related cases diagnosed between 2008 and 2010. Median survival rates in the test group were:

  • Good - 26 months
  • Intermediate - 13 months
  • Poor - 7 months.

"We believe this model will facilitate development of risk-adapted treatment strategies for patients with treatment-related myelodysplastic syndromes," Garcia-Manero said.


'/>"/>
Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Strong evidence supports prognostic value of circulating tumor cells in breast cancer
2. A novel prognostic marker for biliary atresia
3. Prognostic markers for prostate cancer patients who receive radiation after surgery
4. A prognostic and predictive biomarker for nonsmall cell lung cancer
5. "IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do
6. Model shows how façade pollutants make it into the environment
7. Supercomputer reveals new details behind drug-processing protein model
8. Funding models not associated with better preventive care delivery
9. When errors improve performance: Model describes how experiences influence our perception
10. New Stanford model establishes guidelines for earlier cancer detection
11. UGA researchers develop first mouse model to study important aspect of Alzheimer’s
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Prognostic model developed for MDS related to prior cancer therapy
(Date:5/28/2015)... RI (PRWEB) May 28, 2015 As the ... beach to keep cool. It’s important to make safety a ... is sharing some swimming tips. , According to the Centers ... in the United States, not including boating incidents. Additionally, the ... death for children ages 1 to 4. , Amica ...
(Date:5/28/2015)... Lauderdale, Florida (PRWEB) May 28, 2015 ... Havlicek, and wife Beth, both Genesis Foundation Board of ... Annual John Havlicek Celebrity Fishing Tournament June 4-7. For ... this 4-day event benefitting The Genesis Foundation for children ... the cause. , The 34th John Havlicek Celebrity ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 The CEO ... announced a just launched blog series which provides analysis ... Hosted on the “R. Bruce Dalglish” profile on Blogger.com, ... R. Bruce Dalglish’s corporate experience. , “Throughout my ... workplace cultures have upon the overall success of businesses,” ...
(Date:5/28/2015)... 2015 Nidra Herbal Sleep Supplement features a ... body. A non-addictive supplement, Nidra Herbal Sleep Supplement is more ... will leave users with a real sense of wellbeing the ... Ayurveda, which translates as the “Science or Knowledge of Life”, ... and is a holistic system of knowledge which combines contemplation, ...
(Date:5/28/2015)... 2015 Baptist Medical Center Jacksonville has ... from acute stroke or other neurological conditions. , The ... a few in the country and the first in ... such as brain aneurysms. , “Baptist Health is ... patients who are impacted by stroke,” said Nicole Thomas, ...
Breaking Medicine News(10 mins):Health News:Splash! Amica Shares 6 Swimming Safety Tips 2Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2Health News:Ayurveda Herba Corp’s Revolutionary Herbal Sleep Supplement is Now Available from Amazon.com 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 3
... , HOUSTON , Feb. 8 ... technology are invited to visit the NASA Goes the Distance exhibit ... Expo at the Palmer Event Center. NASA,s exhibit will be open ... 10 a.m. to 6 p.m. Saturday . The exhibit will ...
... MONDAY, Feb. 8 (HealthDay News) -- Decreased handgrip strength in ... say. , In a new study, handgrip strength was measured ... group of 555 participants in the Netherlands. The researchers found ... a greater decline in strength over time, was associated with ...
... New York,s ... , ... February 8, 2010 -- As a proactive measure, New York City and the Environmental Protection ... with the support of personal injury attorneys. As reported by The New York Times ...
... , Feb. 8 Aton Pharma, Inc., a ... Richardson has joined the company as Vice President, Commercial ... Donald A. Fishbein assumes the same role for the ... Holdings LLC, Aton is focused on the development and commercialization ...
... , , , , , ... Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheet: ... botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today,that it ... fiscal year ended, October 31, 2009 on time. In ...
... ... NuEarth Corporation (Pinksheets: NUEC) (“NuEarth”), a manufacturer and ... that the company’s Laboratory and Research Division “TerraSolv SA” has ... contract representing an additional $1.3 Million laboratory service contract with ...
Cached Medicine News:Health News:NASA Joins Austin Marathon Expo, Inspires Students 2Health News:Handgrip Strength Helps Predict Death Risk in Elderly 2Health News:New York Examines Possible Contamination in Public City Schools 2Health News:Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 3Health News:NuEarth Signs $1.3 Million Laboratory Contract 2Health News:NuEarth Signs $1.3 Million Laboratory Contract 3
(Date:5/28/2015)... --  Clementia Pharmaceuticals, Inc. today announced that ... (Part B) of its natural history study in ... severely disabling congenital myopathy characterized by painful, recurrent ... in the formation of new, abnormal (heterotopic) bone ... The multi-center, non-interventional, two-part longitudinal study is designed ...
(Date:5/28/2015)... SAN DIEGO , May 28, 2015 ... immuno-oncology drug development company, announced today that its President ... present at the LD Micro Invitational Investor Conference ... Bel Air, California on June ... corporate update including highlights from the significant progress made ...
(Date:5/28/2015)... IRVING, Texas , May 28, 2015 /PRNewswire/ ... on fulfilling the promise of precision medicine, today ... cohort studies that demonstrate the utility of Caris ... service, in characterizing mechanisms of drug resistance and ... presented May 31 in poster sessions at the ...
Breaking Medicine Technology:Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 2Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 3MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 2MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 3MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 4Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 2Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 3Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 4Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 5
... Va. , Feb. 3 CEL-SCI Corporation ... Officer, will be presenting at the 2010 BIO CEO & Investor ... take place February 8-9 at the Waldorf=Astoria in ... Tuesday, February 9th , at 1:30 p.m. EST .  The ...
... , Feb. 3 Repligen Corporation (Nasdaq: RGEN ... from the United States Patent and Trademark Office for a patent ... structure to the commercial form of Protein A from Staphylococcus ... the world,s approved monoclonal antibodies . The patent, which ...
Cached Medicine Technology:CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference 2Repligen Receives Notice of Allowance for Recombinant Protein A Patent 2Repligen Receives Notice of Allowance for Recombinant Protein A Patent 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: